BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 25417733)

  • 21. Clinical validation of FDG-PET/CT in the radiation treatment planning for patients with oesophageal cancer.
    Muijs CT; Beukema JC; Woutersen D; Mul VE; Berveling MJ; Pruim J; van der Jagt EJ; Hospers GA; Groen H; Plukker JT; Langendijk JA
    Radiother Oncol; 2014 Nov; 113(2):188-92. PubMed ID: 25467002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
    Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy.
    Lee E; Zeng J; Miyaoka RS; Saini J; Kinahan PE; Sandison GA; Wong T; Vesselle HJ; Rengan R; Bowen SR
    Med Phys; 2017 Jul; 44(7):3418-3429. PubMed ID: 28453861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Radiotherapy volume delineation based on (
    Encaoua J; Abgral R; Leleu C; El Kabbaj O; Caradec P; Bourhis D; Pradier O; Schick U
    Cancer Radiother; 2017 Jun; 21(4):267-275. PubMed ID: 28499658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study.
    Servagi-Vernat S; Differding S; Sterpin E; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
    Acta Oncol; 2015 Jul; 54(7):1008-16. PubMed ID: 25562382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18)FDG-PET/CT for esophageal cancer.
    Yu W; Cai XW; Liu Q; Zhu ZF; Feng W; Zhang Q; Zhang YJ; Yao ZF; Fu XL
    Radiother Oncol; 2015 Feb; 114(2):195-200. PubMed ID: 25586952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consequences of additional use of contrast-enhanced (18)F-FDG PET/CT in target volume delineation and dose distribution for pancreatic cancer.
    Li XX; Liu NB; Zhu L; Yuan XK; Yang CW; Ren P; Gong LL; Zhao LJ; Xu WG; Wang P
    Br J Radiol; 2015 Jul; 88(1051):20140590. PubMed ID: 25939819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic values of mid-radiotherapy
    Kim N; Cho H; Yun M; Park KR; Lee CG
    Radiat Oncol; 2019 Feb; 14(1):27. PubMed ID: 30717809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer.
    Leong T; Everitt C; Yuen K; Condron S; Hui A; Ngan SY; Pitman A; Lau EW; MacManus M; Binns D; Ackerly T; Hicks RJ
    Radiother Oncol; 2006 Mar; 78(3):254-61. PubMed ID: 16545881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is image registration of fluorodeoxyglucose-positron emission tomography/computed tomography for head-and-neck cancer treatment planning necessary?
    Fried D; Lawrence M; Khandani AH; Rosenman J; Cullip T; Chera BS
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):748-54. PubMed ID: 22414285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.
    Ding X; Li H; Wang Z; Huang W; Li B; Zang R; Sun H; Yi Y
    Technol Cancer Res Treat; 2013 Jun; 12(3):251-7. PubMed ID: 23289475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous modulated accelerated radiation therapy for esophageal cancer: a feasibility study.
    Zhang WZ; Chen JZ; Li DR; Chen ZJ; Guo H; Zhuang TT; Li DS; Zhou MZ; Chen CZ
    World J Gastroenterol; 2014 Oct; 20(38):13973-80. PubMed ID: 25320535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining the target in cancer of the oesophagus: direct radiotherapy planning with fluorodeoxyglucose positron emission tomography-computed tomography.
    le Grange F; Wickers S; Warry A; Warrilow J; Bomanji J; Tobias JS
    Clin Oncol (R Coll Radiol); 2015 Mar; 27(3):160-7. PubMed ID: 25540907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study.
    Yue J; Chen L; Cabrera AR; Sun X; Zhao S; Zheng F; Han A; Zheng J; Teng X; Ma L; Ma Y; Han D; Zhao X; Mu D; Yu J; Li Y
    J Nucl Med; 2010 Apr; 51(4):528-34. PubMed ID: 20237030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Geometrical differences in target volumes based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography and four-dimensional computed tomography maximum intensity projection images of primary thoracic esophageal cancer.
    Guo Y; Li J; Wang W; Zhang Y; Wang J; Duan Y; Shang D; Fu Z
    Dis Esophagus; 2014; 27(8):744-50. PubMed ID: 24915760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [¹⁸F]fluorodeoxyglucose uptake patterns in lung before radiotherapy identify areas more susceptible to radiation-induced lung toxicity in non-small-cell lung cancer patients.
    Petit SF; van Elmpt WJ; Oberije CJ; Vegt E; Dingemans AM; Lambin P; Dekker AL; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):698-705. PubMed ID: 20884128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Volumetric-modulated arc therapy (RapidArc) vs. conventional fixed-field intensity-modulated radiotherapy for ¹⁸F-FDG-PET-guided dose escalation in oropharyngeal cancer: a planning study.
    Teoh M; Beveridge S; Wood K; Whitaker S; Adams E; Rickard D; Jordan T; Nisbet A; Clark CH
    Med Dosim; 2013; 38(1):18-24. PubMed ID: 22841937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
    Ashamalla H; Rafla S; Parikh K; Mokhtar B; Goswami G; Kambam S; Abdel-Dayem H; Guirguis A; Ross P; Evola A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1016-23. PubMed ID: 15979817
    [TBL] [Abstract][Full Text] [Related]  

  • 39.  ¹⁸F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose.
    Massaccesi M; Calcagni ML; Spitilli MG; Cocciolillo F; Pelligrò F; Bonomo L; Valentini V; Giordano A
    Radiat Oncol; 2012 Jul; 7():106. PubMed ID: 22781363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy.
    Leclerc M; Lartigau E; Lacornerie T; Daisne JF; Kramar A; Grégoire V
    Radiother Oncol; 2015 Jul; 116(1):87-93. PubMed ID: 26088157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.